Post COVID-19 Persistent Symptoms: Far More Common than Expected

After the acute phase of COVID-19 infection, we commonly observe persistent symptoms that can alter functionality and quality of life. 

Síntomas persistentes post COVID-19: mucho más frecuentes de lo que creíamos

Persistent symptoms are those that continue at least 60 days after diagnosis or at least 30 days after recovery from the acute phase, or after discharge. 

Many of the studies included in this review have shown that over 70% of patients requiring hospitalization had at least one persistent symptom after discharge. Among the most common persistent symptoms we found dyspnea (36%), fatigue (40%) and insomnia or sleeping disorders (29.4%).

Studies analyzed in this JAMA review were heterogeneous, which limits interpretation and comparison. Major differences were patient populations and definitions of time zero (diagnosis, symptom onset, hospital discharge, etc.).


Read also: Efficacy of the Sinopharm Vaccine Against COVID-19.


Evidently, in order to be able to analyze and describe persistent symptoms, we need followup time, something we do not have at present. Regardless study heterogeneity, we have been able to conclude persistent symptoms are quite frequent, even the rule. 

nasserie-2021-oi-210337-1621437711-33721

Original Title: Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19. A Systematic Review.

Reference: Tahmina Nasserie et al. JAMA Network Open. 2021;4(5):e2111417. doi:10.1001/jamanetworkopen.2021.11417.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Is the Booster Dose Against COVID-19 Effective for All Ages?

The answer is incontrovertible: it is undeniably effective. For all ages, the confirmed COVID19 and severe case rates were significantly lower for patients who...

Pfizer Booster Dose Efficacy against Omicron

The BNT162b2 vaccine (Pfizer/BioNTech) has previously shown a 95% efficacy against COVID-19. This efficacy has been changing with the surge of new variants and,...

Once Again, the Omicron Variant Tests the Limits of Healthcare Systems, But with Hope

The latest significant COVID-19 variant, the Omicron, is again pushing healthcare systems around the world onto the verge of collapse, having reached over 300...

The Most Read Articles of 2021: COVID-19

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on COVID-19. Follow...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....